Megestrol Acetate With or Without Mirtazapine in Treating Cancer Patients With Weight Loss or Loss of Appetite
Status:
Withdrawn
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies the safety and efficacy of megestrol acetate given
with or without mirtazapine in treating cancer patients with weight loss and loss of
appetite. To date, no pharmacologic interventions have been approved by FDA to treat cancer
anorexia-cachexia syndrome (CACS). Megestrol acetate has been shown to increase appetite in
cancer patients. Adding mirtazapine may provide a much more effective treatment and help
improve quality of life.